Haematological Malignancies, Multiple Myeloma
Serum Free Light Chain Assays—Their Role in Multiple Myeloma
Robert A Kyle
Globally, multiple myeloma (MM) accounts for 0.8% of all cancer deaths, with a survival rate of 50% of those enrolled in clinical trials.1,2 It is the most common bone marrow cancer in Europe, with over 77,000 patients undergoing treatment at any one time.3 In the US, MM is the second most common haematological malignancy, affecting […]